vs
AeroVironment Inc（AVAV）与ICU MEDICAL INC（ICUI）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是AeroVironment Inc的1.1倍（$540.7M vs $472.5M），ICU MEDICAL INC净利率更高（-2.9% vs -3.6%，领先0.7%），AeroVironment Inc同比增速更快（181.9% vs -14.1%），ICU MEDICAL INC自由现金流更多（$36.0M vs $-55.9M），过去两年AeroVironment Inc的营收复合增速更高（59.1% vs -2.3%）
AeroVironment是1971年由人力飞机设计师保罗·麦克里迪创立的美国国防科技企业，总部位于弗吉尼亚州阿灵顿，专注于自主系统、反无人机系统及航天系统的研发制造，为美国国防部及多国军方供应渡鸦、弹簧刀、黄蜂、美洲狮等系列中小型无人机产品。
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
AVAV vs ICUI — 直观对比
营收规模更大
ICUI
是对方的1.1倍
$472.5M
营收增速更快
AVAV
高出196.0%
-14.1%
净利率更高
ICUI
高出0.7%
-3.6%
自由现金流更多
ICUI
多$91.8M
$-55.9M
两年增速更快
AVAV
近两年复合增速
-2.3%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $472.5M | $540.7M |
| 净利润 | $-17.1M | $-15.7M |
| 毛利率 | 22.0% | 37.5% |
| 营业利润率 | -6.4% | 1.0% |
| 净利率 | -3.6% | -2.9% |
| 营收同比 | 181.9% | -14.1% |
| 净利润同比 | -875.1% | 34.0% |
| 每股收益（稀释后） | $-0.34 | $-0.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVAVICUI
| Q4 25 | $472.5M | $540.7M | ||
| Q3 25 | $454.7M | $537.0M | ||
| Q2 25 | $275.1M | $548.9M | ||
| Q1 25 | $167.6M | $604.7M | ||
| Q4 24 | $188.5M | $629.8M | ||
| Q3 24 | $189.5M | $589.1M | ||
| Q2 24 | $197.0M | $596.5M | ||
| Q1 24 | $186.6M | $566.7M |
净利润AVAVICUI
| Q4 25 | $-17.1M | $-15.7M | ||
| Q3 25 | $-67.4M | $-3.4M | ||
| Q2 25 | $16.7M | $35.3M | ||
| Q1 25 | $-1.8M | $-15.5M | ||
| Q4 24 | $7.5M | $-23.8M | ||
| Q3 24 | $21.2M | $-33.0M | ||
| Q2 24 | $6.0M | $-21.4M | ||
| Q1 24 | $13.9M | $-39.5M |
毛利率AVAVICUI
| Q4 25 | 22.0% | 37.5% | ||
| Q3 25 | 20.9% | 37.4% | ||
| Q2 25 | 36.5% | 37.9% | ||
| Q1 25 | 37.7% | 34.7% | ||
| Q4 24 | 39.1% | 36.1% | ||
| Q3 24 | 43.0% | 34.8% | ||
| Q2 24 | 38.4% | 34.8% | ||
| Q1 24 | 36.1% | 32.7% |
营业利润率AVAVICUI
| Q4 25 | -6.4% | 1.0% | ||
| Q3 25 | -15.2% | 2.6% | ||
| Q2 25 | 5.0% | 1.9% | ||
| Q1 25 | -1.8% | 2.1% | ||
| Q4 24 | 3.7% | 6.0% | ||
| Q3 24 | 12.2% | 1.4% | ||
| Q2 24 | 3.0% | 1.3% | ||
| Q1 24 | 7.7% | -1.9% |
净利率AVAVICUI
| Q4 25 | -3.6% | -2.9% | ||
| Q3 25 | -14.8% | -0.6% | ||
| Q2 25 | 6.1% | 6.4% | ||
| Q1 25 | -1.0% | -2.6% | ||
| Q4 24 | 4.0% | -3.8% | ||
| Q3 24 | 11.2% | -5.6% | ||
| Q2 24 | 3.1% | -3.6% | ||
| Q1 24 | 7.4% | -7.0% |
每股收益（稀释后）AVAVICUI
| Q4 25 | $-0.34 | $-0.63 | ||
| Q3 25 | $-1.44 | $-0.14 | ||
| Q2 25 | $0.59 | $1.43 | ||
| Q1 25 | $-0.06 | $-0.63 | ||
| Q4 24 | $0.27 | $-0.97 | ||
| Q3 24 | $0.75 | $-1.35 | ||
| Q2 24 | $0.18 | $-0.88 | ||
| Q1 24 | $0.50 | $-1.63 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $588.5M | — |
| 总债务越低越好 | $747.5M | — |
| 股东权益账面价值 | $4.4B | $2.1B |
| 总资产 | $5.6B | $4.1B |
| 负债/权益比越低杠杆越低 | 0.17× | — |
8季度趋势，按日历期对齐
现金及短期投资AVAVICUI
| Q4 25 | $588.5M | — | ||
| Q3 25 | $685.8M | — | ||
| Q2 25 | $40.9M | — | ||
| Q1 25 | $47.0M | — | ||
| Q4 24 | $69.0M | $308.6M | ||
| Q3 24 | $81.2M | $312.5M | ||
| Q2 24 | $73.3M | $302.6M | ||
| Q1 24 | $107.7M | $251.4M |
总债务AVAVICUI
| Q4 25 | $747.5M | — | ||
| Q3 25 | $747.5M | — | ||
| Q2 25 | $30.0M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $15.0M | — | ||
| Q3 24 | $17.5M | — | ||
| Q2 24 | $28.0M | — | ||
| Q1 24 | $40.0M | — |
股东权益AVAVICUI
| Q4 25 | $4.4B | $2.1B | ||
| Q3 25 | $4.4B | $2.1B | ||
| Q2 25 | $886.5M | $2.1B | ||
| Q1 25 | $861.1M | $2.0B | ||
| Q4 24 | $858.4M | $2.0B | ||
| Q3 24 | $845.5M | $2.0B | ||
| Q2 24 | $822.7M | $2.0B | ||
| Q1 24 | $813.0M | $2.1B |
总资产AVAVICUI
| Q4 25 | $5.6B | $4.1B | ||
| Q3 25 | $5.6B | $4.1B | ||
| Q2 25 | $1.1B | $4.1B | ||
| Q1 25 | $1.0B | $4.2B | ||
| Q4 24 | $1.0B | $4.2B | ||
| Q3 24 | $999.2M | $4.3B | ||
| Q2 24 | $1.0B | $4.3B | ||
| Q1 24 | $980.3M | $4.3B |
负债/权益比AVAVICUI
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | 0.03× | — | ||
| Q1 25 | 0.03× | — | ||
| Q4 24 | 0.02× | — | ||
| Q3 24 | 0.02× | — | ||
| Q2 24 | 0.03× | — | ||
| Q1 24 | 0.05× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-45.1M | $60.6M |
| 自由现金流经营现金流 - 资本支出 | $-55.9M | $36.0M |
| 自由现金流率自由现金流/营收 | -11.8% | 6.6% |
| 资本支出强度资本支出/营收 | 2.3% | 4.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-240.7M | $91.8M |
8季度趋势，按日历期对齐
经营现金流AVAVICUI
| Q4 25 | $-45.1M | $60.6M | ||
| Q3 25 | $-123.7M | $56.7M | ||
| Q2 25 | $-264.0K | $11.2M | ||
| Q1 25 | $-25.8M | $51.3M | ||
| Q4 24 | $-3.6M | $40.2M | ||
| Q3 24 | $28.4M | $36.1M | ||
| Q2 24 | $-11.7M | $82.0M | ||
| Q1 24 | $52.6M | $45.8M |
自由现金流AVAVICUI
| Q4 25 | $-55.9M | $36.0M | ||
| Q3 25 | $-146.5M | $27.6M | ||
| Q2 25 | $-8.8M | $-8.5M | ||
| Q1 25 | $-29.6M | $36.7M | ||
| Q4 24 | $-8.7M | $16.1M | ||
| Q3 24 | $22.9M | $16.2M | ||
| Q2 24 | $-20.8M | $62.5M | ||
| Q1 24 | $48.8M | $29.9M |
自由现金流率AVAVICUI
| Q4 25 | -11.8% | 6.6% | ||
| Q3 25 | -32.2% | 5.1% | ||
| Q2 25 | -3.2% | -1.5% | ||
| Q1 25 | -17.7% | 6.1% | ||
| Q4 24 | -4.6% | 2.6% | ||
| Q3 24 | 12.1% | 2.7% | ||
| Q2 24 | -10.5% | 10.5% | ||
| Q1 24 | 26.1% | 5.3% |
资本支出强度AVAVICUI
| Q4 25 | 2.3% | 4.6% | ||
| Q3 25 | 5.0% | 5.4% | ||
| Q2 25 | 3.1% | 3.6% | ||
| Q1 25 | 2.3% | 2.4% | ||
| Q4 24 | 2.7% | 3.8% | ||
| Q3 24 | 2.9% | 3.4% | ||
| Q2 24 | 4.6% | 3.3% | ||
| Q1 24 | 2.0% | 2.8% |
现金转化率AVAVICUI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.02× | 0.32× | ||
| Q1 25 | — | — | ||
| Q4 24 | -0.48× | — | ||
| Q3 24 | 1.34× | — | ||
| Q2 24 | -1.93× | — | ||
| Q1 24 | 3.79× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVAV
| Services | $130.2M | 28% |
| Cost Plus | $95.8M | 20% |
| Uncrewed Aircraft Systems | $89.8M | 19% |
| Space And Directed Energy | $53.2M | 11% |
| Non U.s.Government | $42.2M | 9% |
| TM | $31.9M | 7% |
| Other | $30.7M | 7% |
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
